SX-576 is a small molecule CXCR1/2 antagonist that potently blocks the migration of neutrophils to sites of injury and/or inflammation. SX-576 is being developed as a potential therapeutic for the treatment of pulmonary inflammatory diseases, such as bronchopulmonary dysplasia (BPD) and chronic obstructive pulmonary disease (COPD). In this study, the pharmacokinetic properties of SX-576 will be optimized through chemical structure modification and formulation development. The new analogs and formulations will be evaluated for activity in isolated human neutrophils, and for improved oral bioavailability in pharmacokinetic studies. A preclinical candidate will be selected and evaluated in a rat model of pulmonary inflammation. A process for the large scale preparation and formulation of the preclinical lead compound will be developed, followed by toxicology studies to assess its safety. At the conclusion of this study, the necessary information for an Investigational New Drug (IND) application for clinical evaluation in humans will have been collected. In summary, the successful completion of this study would advance a potential new treatment for pulmonary inflammatory diseases, thereby advancing the mission of the NIH to lessen the burdens of illness in our society.

Public Health Relevance

Pulmonary inflammatory diseases such as bronchopulmonary dysplasia (BPD) and chronic obstructive pulmonary disease (COPD) affect more than 12 million people in the U.S., and represent a significant burden to public health. This Phase II competing renewal would advance a novel anti-inflammatory drug towards clinical evaluation in patients suffering from pulmonary inflammatory disease.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Blaisdell, Carol J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Syntrix Biosystems, Inc.
United States
Zip Code
Lu, Xin; Horner, James W; Paul, Erin et al. (2017) Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 543:728-732
Maeda, Dean Y; Peck, Angela M; Schuler, Aaron D et al. (2015) Boronic acid-containing CXCR1/2 antagonists: Optimization of metabolic stability, in vivo evaluation, and a proposed receptor binding model. Bioorg Med Chem Lett 25:2280-4
Schuler, Aaron D; Engles, Courtney A; Maeda, Dean Y et al. (2015) Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability. Bioorg Med Chem Lett 25:3793-7
Maeda, Dean Y; Peck, Angela M; Schuler, Aaron D et al. (2014) Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2. J Med Chem 57:8378-97
Maeda, Dean Y; Quinn, Mark T; Schepetkin, Igor A et al. (2010) Nicotinamide glycolates antagonize CXCR2 activity through an intracellular mechanism. J Pharmacol Exp Ther 332:145-52
Kallapur, Suhas G; Moss, Timothy J M; Auten Jr, Richard L et al. (2009) IL-8 signaling does not mediate intra-amniotic LPS-induced inflammation and maturation in preterm fetal lamb lung. Am J Physiol Lung Cell Mol Physiol 297:L512-9